Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization

International Journal of Clinical Oncology

Volumn 9, Issue 5, 2004, Pages 373-377

  Okamura, Takehiko ^a   Umemoto, Yukihiro ^a   Yasui, Takahiro ^a   Saiki, Shigeru ^b   Kuroda, Hideya ^b   Kotoh, Shuji ^c   Kamizaki, Hitonori ^c  

^a Meijo Hospital   (Japan)

^b Ohtemae Hospital   (Japan)

^c HAMANOMACHI HOSPITAL   (Japan)

Author keywords

Bladder cancer; Chromosomes 9 and 17; Fluorescence in situ hybridization; Urine sample

Indexed keywords

TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CHROMOSOME 17; CHROMOSOME 9; CHROMOSOME NUMBER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; URINE; URINE CYTOLOGY;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

EID: 10944248318     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-004-0419-z     Document Type: Article

References (23)

1. Slaton JW, Benedict WF, Dinney CPN (2001) P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57:852-859
2. Simoneau AR, Jones PA (1994) Bladder cancer: the molecular progression to invasive disease. World J Urol 12:89-95
3. Fujimoto K, Yamada Y, Okajima E, et al. (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52:1393-1398
4. Lu M-L, Wikman F, Orntoft TF, et al. (2002) Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 8:171-179
5. Chan MWY, Chan LW, Tang NLS, et al. (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8:464-470
6. Asamoto M, Iwahori Y, Okamura T, et al. (1997) Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas. Jpn J Clin Oncol 27:22-25
7. Okamura T, Akita H, Kawai N, et al. (1998) Immunohistochemical evaluation of p53, PCNA and bcl-2 expression during BCG intravesical instillation therapy for superficial bladder cancers. Urol Res 26:161-164
8. Nisman B, Barak V, Shapiro A, et al. (2002) Evaluation of urine cyfra 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94:2914-2922
9. Cheng L, Reiter RE, Jin Y, et al. (2003) Immunocytochemical analysis of prostate stem cell antigen as an adjunct marker for the detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol 169:2094-2100
10. Lokeshwar VB, Schroeder GL, Selzer MG, et al. (2002) Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat test. Cancer 95:61-72
11. Halling KC, King W, Sokolova IA, et al. (2002) A comparison of BTA Stat, hemoglobin dipstick, telomerase and Vysis Urovysion assays for the detection of urothelial carcinoma in urine. J Urol 167:2001-2006
12. Poulakis V, Witzsch U, Vries RDE, et al. (2001) A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int 88:692-701
13. Saad A, Hanbury DC, McNicholas TA, et al. (2002) A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 89:369-373
14. Chahal R, Darshane A, Browning AJ, et al. (2001) Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder. Eur Urol 40:415-421
15. Kunitomo K, Takehara T, Inoue S, et al. (2002) Detection of c-erbB-2 (HER-2/neu) amplification in breast carcinoma by fluorescence in situ hybridization on tissue sections and imprinted cells. Pathol Int 52:451-457
16. Nakamura H, Saji H, Idiris A, et al. (2003) Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 9:2294-2299
17. Barrans SL, Evans PAS, O'Connor SJM, et al. (2003) The t(14:18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 9:2133-2139
18. Shono T, Sakai H, Takehara K, et al. (2002) Analysis of numerical chromosomal aberrations in adrenal cortical neoplasms by fluorescence in situ hybridization. J Urol 168:1370-1373
19. Skacel M, Fahmy M, Brainard JA, et al. (2003) Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169:2101-2105
20. Salosdy MF, Schellhammer P, Bokinsky G, et al. (2002) Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168:1950-1954
21. Bubendorf L, Grilli B, Sauter G, et al. (2001) Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116:79-86
22. Nabi G, Greene DR, O'Donnell M. (2003) How important is urinary cytology in the diagnosis of urological malignancies? Eur Urol 43:632-636
23. Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170:438-441